BEDMINSTER, N.J., and DUBLIN, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it now has 30 patents issued or allowed by the United States Patent and Trademark Office (USPTO) related to its flagship product, Vascepa ® (icosapent ethyl) capsules. Amarin recently received Notices of Allowance for U.S. Patent Application Serial Numbers 13/777,398, 13/768,897, and 13/768,869, each titled "Stable Pharmaceutical Composition and Methods of Using Same." The scope of coverage related to Vascepa represented by these applications is the broadest allowed to date. "With 30 patents issued and allowed and over 30 additional applications pending in the United States, Amarin now has one of the most extensive, and expanding, patent portfolios covering a product in the industry," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "Amarin is pleased that the USPTO continues to recognize the novel characteristics of Vascepa. The continued issuance of a variety of patents covering Vascepa is emblematic of the success achieved at Amarin toward its goal of protecting the commercial potential of Vascepa to beyond 2030 through patent protection. In addition, Amarin's Vascepa is also protected by trade secrets and existing manufacturing barriers to entry, along with anticipated three- or five-year regulatory exclusivity in the United States." Amarin is also making significant progress with its patent applications related to Vascepa in multiple jurisdictions outside the United States, including the May 2013 patent grant by the European Patent Office covering the use of Vascepa based on the results from the MARINE trial. About Amarin Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa ® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com. Forward-looking statements This press release contains forward-looking statements, including statements about whether the subject patents would be issued and adequately protect Vascepa against competition, Amarin's plan to protect the commercial potential of Vascepa, and the future status of pending patent applications. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: events that could interfere with the issuance of a patent, or once issued, the continued validity or enforceability of a patent; Amarin's ability generally to maintain adequate patent protection and successfully enforce patent claims against third parties; commercializing Vascepa without violating the intellectual property rights of others; and uncertainties associated generally with research and development, clinical trials and related regulatory approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Availability of other information about AmarinInvestors and others should note that we communicate with our investors and the public using our company website ( www.amarincorp.com), our investor relations website ( http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
CONTACT: Amarin contact information: Joseph Bruno Investor Relations and Corporate Communications Amarin Corporation In U.S.: +1 (908) 719-1315 firstname.lastname@example.org